Please use this identifier to cite or link to this item: http://hdl.handle.net/20.500.12857/126945
DC FieldValueLanguage
dc.contributor.authorComelli, Ivanen
dc.contributor.authorPigna, Federicaen
dc.contributor.authorCervellin, Gianfrancoen
dc.date.accessioned2020-03-15T18:28:50Z-
dc.date.available2020-03-15T18:28:50Z-
dc.date.issued2018en
dc.identifier.issn07356757en
dc.identifier.urihttp://hdl.handle.net/20.500.12857/126945-
dc.description.abstractClass Ic antiarrhythmic agents flecainide and propafenone are amongst the drugs most frequently prescribed to control atrial arrhythmias, in particular atrial fibrillation (AF). Despite being cited in some guidelines as a warning when using 1c antiarrhythmic agents, atrial flutter (AFl) with 1:1 atrioventricular conduction is rare in adults, with only small series reported in the literature, mainly including patients having 1:1 AFl during physical activity, and often associated with a predisposing factor, namely a dual AV nodal conduction pathway. We describe here a rare case of 1:1 AFl induced by flecainide, developing whilst the patients was resting in bed, in a 56 year old man who presented to the local Emergency Department (ED) complaining for palpitations due to acute-onset AF. After ED discharge, the patient was then evaluated in the Arrhythmologic Clinic of the Cardiology Department, and channellopaties were excluded. This case report should raise alertness in emergency physicians about this serious and potentially fatal side effect of flecainide, when using this drug for pharmacological cardioversion of AF.en
dc.language.isoenen
dc.publisherW B SAUNDERS CO-ELSEVIER INCen
dc.relation.ispartofThe American journal of emergency medicineen
dc.subject1:1 atrial flutteren
dc.subject1c-dependent atrial flutteren
dc.subjectAtrial fibrillationen
dc.subjectAtrial flutteren
dc.subjectFlecainideen
dc.subject.meshAtrial Fibrillationen
dc.subject.meshAtrial Flutteren
dc.subject.meshFlecainideen
dc.title1:1 atrial flutter induced by flecainide, whilst the patient was at resten
dc.typeCase Reportsen
dc.typeJournal Articleen
dc.identifier.doi10.1016/j.ajem.2018.07.040en
dc.identifier.pmid30033133en
dc.identifier.scopus2-s2.0-85050094976en
dc.identifier.isiWOS:000447152300057en
dc.identifier.urlhttps://api.elsevier.com/content/abstract/scopus_id/85050094976en
dc.relation.volume36en
dc.relation.issue11en
dc.relation.firstpage2131.e3-2131.e5en
dc.identifier.eissn1532-8171en
dc.relation.lastpage2131.e5en
dc.source.typearen
dc.publisher.place1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USAen
dc.subject.keywordsplusI ANTIARRHYTHMIC DRUGSen
dc.subject.keywordsplusFIBRILLATIONen
dc.subject.keywordsplusCONDUCTIONen
dc.subject.meshsecondaryElectrocardiographyen
dc.subject.meshsecondaryEmergency Service, Hospitalen
dc.subject.meshsecondaryHumansen
dc.subject.meshsecondaryInjections, Intravenousen
dc.subject.meshsecondaryMaleen
dc.subject.meshsecondaryMiddle Ageden
dc.subject.meshtermsAtrial Fibrillation/drug therapyen
dc.subject.meshtermsAtrial Flutter/chemically induceden
dc.subject.meshtermsFlecainide/adverse effectsen
dc.subject.meshtermssecondaryAtrial Flutter/physiopathologyen
dc.subject.meshtermssecondaryFlecainide/administration & dosageen
dc.contributor.affiliationEmergency Department, Academic Hospital of Parma, Parma, Italy.en
dc.contributor.affiliationEmergency Department, Academic Hospital of Parma, Parma, Italy.en
dc.contributor.affiliationEmergency Department, Academic Hospital of Parma, Parma, Italy. Electronic address: gcervellin@ao.pr.it.en
item.languageiso639-1en-
item.fulltextNo Fulltext-
item.openairetypeCase Reports-
item.openairetypeJournal Article-
item.grantfulltextnone-
crisitem.author.deptUNIVERSITÀ DI VERONA-
crisitem.author.orcid0000-0002-7723-7239-
Appears in Collections:Articles
Show simple item record

PubMed Central
Citations 50

1
Last Week
1
Last month
checked on May 2, 2021

WEB OF SCIENCETM
Citations

3
checked on Jun 29, 2022

Page view(s) 20

1
checked on Jun 30, 2022

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.